OBJECTIVES: In light of the high prevalence of sleep disorders in patients suffering from posttraumatic stress disorder (PTSD), this study sought to compare the effect of prazosin and hydroxyzine on sleep quality in this patient group. METHODS: A total of 100 patients suffering from PTSD were assessed (mean age = 35.51 years, SD = 6.41; 28% females). Next, they were randomly assigned to one of three treatment groups: prazosin (33 patients), hydroxyzine (34 patients) or placebo (33 patients). The trial lasted for 8 weeks. The patients' sleep quality was assessed using the Pittsburgh Sleep Quality Index. Items taken from the Mini International Neuropsychiatric Interview were used to operationalize PTSD. RESULTS: Compared to controls, patients treated with prazosin and hydroxyzine reported improved sleep and less nightmares. Improvement was greatest in patients treated with prazosin compared to hydroxyzine and placebo. Improvement in sleep was associated with an amelioration of their PTSD symptoms. CONCLUSION: Both prazosin and hydroxyzine can be used to treat psychopharmacological sleep disorders and nightmares in patients suffering from PTSD, also leading to reductions in PTSD symptoms.
RCT Entities:
OBJECTIVES: In light of the high prevalence of sleep disorders in patients suffering from posttraumatic stress disorder (PTSD), this study sought to compare the effect of prazosin and hydroxyzine on sleep quality in this patient group. METHODS: A total of 100 patients suffering from PTSD were assessed (mean age = 35.51 years, SD = 6.41; 28% females). Next, they were randomly assigned to one of three treatment groups: prazosin (33 patients), hydroxyzine (34 patients) or placebo (33 patients). The trial lasted for 8 weeks. The patients' sleep quality was assessed using the Pittsburgh Sleep Quality Index. Items taken from the Mini International Neuropsychiatric Interview were used to operationalize PTSD. RESULTS: Compared to controls, patients treated with prazosin and hydroxyzine reported improved sleep and less nightmares. Improvement was greatest in patients treated with prazosin compared to hydroxyzine and placebo. Improvement in sleep was associated with an amelioration of their PTSD symptoms. CONCLUSION: Both prazosin and hydroxyzine can be used to treat psychopharmacological sleep disorders and nightmares in patients suffering from PTSD, also leading to reductions in PTSD symptoms.
Authors: Sean A P Clouston; Charles B Hall; Minos Kritikos; David A Bennett; Steven DeKosky; Jerri Edwards; Caleb Finch; William C Kreisl; Michelle Mielke; Elaine R Peskind; Murray Raskind; Marcus Richards; Richard P Sloan; Avron Spiro; Neil Vasdev; Robert Brackbill; Mark Farfel; Megan Horton; Sandra Lowe; Roberto G Lucchini; David Prezant; Joan Reibman; Rebecca Rosen; Kacie Seil; Rachel Zeig-Owens; Yael Deri; Erica D Diminich; Bernadette A Fausto; Sam Gandy; Mary Sano; Evelyn J Bromet; Benjamin J Luft Journal: Nat Rev Neurol Date: 2021-11-18 Impact factor: 42.937
Authors: Ihori Kobayashi; Thomas A Mellman; Ashley Cannon; Imani Brown; Linda Boadi; Mary Katherine Howell; Pewu Lavela; Ishaan Sandhu Journal: J Psychiatr Res Date: 2021-12-14 Impact factor: 5.250
Authors: Sudie E Back; Julianne C Flanagan; Jennifer L Jones; Isabel Augur; Alan L Peterson; Stacey Young-McCaughan; David W Shirley; Aisling Henschel; Jane E Joseph; Brett T Litz; Allison K Hancock; John D Roache; Jim Mintz; Jennifer S Wachen; Terence M Keane; Kathleen T Brady Journal: Contemp Clin Trials Date: 2018-08-24 Impact factor: 2.226
Authors: Ye Zhang; Rong Ren; Larry D Sanford; Linghui Yang; Yuenan Ni; Junying Zhou; Jihui Zhang; Yun-Kwok Wing; Jie Shi; Lin Lu; Xiangdong Tang Journal: Sleep Med Date: 2019-06-22 Impact factor: 3.492
Authors: Peter J Colvonen; Laura D Straus; Carl Stepnowsky; Michael J McCarthy; Lizabeth A Goldstein; Sonya B Norman Journal: Curr Psychiatry Rep Date: 2018-06-21 Impact factor: 5.285
Authors: Ben Yang; Javier Sanches-Padilla; Jyothisri Kondapalli; Sage L Morison; Eric Delpire; Rajeshwar Awatramani; D James Surmeier Journal: Neuron Date: 2021-01-20 Impact factor: 18.688